• BSF Enterprise subsidiary Lab-Grown Leather entered partner-funded commercial evaluation agreements with two leading global luxury fashion houses.
• Initial cultivated leather samples were delivered to the first partner, with milestone payments invoiced; the second agreement covers staged evaluation and prototyping.
• Mechanical testing and prototype fabrication are scheduled for the first half of 2027, potentially enabling commercial proof-of-concept and supply agreements that year.
• The material uses 3D Bio-Tissues’ proprietary macromolecular crowding technology, which received a US patent allowance on October 20, 2026.
• Other portfolio companies include Kerato, developing corneal repair therapies, and milieu.bio, supplying proprietary media supplements to biotechnology markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BSF Enterprise plc published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.